Skip to Main content Skip to Navigation
Journal articles

Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer

Abstract : Until recently, drug development in oncology was focused on treating most patients for a specific cancer type without taking in account the heterogeneity between these patients in term of response to treatment. Therefore, this type of broad treatment approach excludes the treatment of patient not responding to disease-specific common drugs. In this review, we focus on the different types of epigenetic drugs currently used as DNA methylation inhibitor agents and their limits in patient care due to their lack of specificity. We also highlight the emergence of a new type of epidrug with higher target specificity due to their original mechanism of action: the disruption of protein complexes involved in the epigenetic modifications.
Document type :
Journal articles
Complete list of metadatas

Cited literature [45 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02484714
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, February 19, 2020 - 3:50:37 PM
Last modification on : Friday, June 19, 2020 - 1:40:18 AM
Long-term archiving on: : Wednesday, May 20, 2020 - 3:34:58 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Pierre-Francois Cartron, Mathilde Cheray, Laurent Bretaudeau. Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer. Epigenomics, Future Medicine, 2019, 12 (2), pp.171-177. ⟨10.2217/epi-2019-0169⟩. ⟨inserm-02484714⟩

Share

Metrics

Record views

177